B
아미노로직스
074430KOSDAQ기초 의약물질 제조업59.5 / 100
Reference Date: 2026-04-13
Financial Score22.0 / 40
News Sentiment12.5 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 3.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AmiNoLogics primarily engages in the manufacturing and sales of raw pharmaceutical materials and amino acid derivative compounds, supplying treatments for conditions such as stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. The pharmaceutical industry operates under strict government regulations, intense competition, and a focus on generic drug development.
Number of Employees
41people
Average Salary
69.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
36.08Industry Average 33.453.0Point
Higher than industry avg (caution)
PBR
2.26Industry Average 2.032.5Point
Higher than industry avg (caution)
ROE
6.54Industry Average -4.293.5Point
Well below industry avg
Debt Ratio
1.09Industry Average 6.618.0Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲5.8% (2-year basis)
Operating Profit Growth Rate
2.0 / 3
Avg ▲9.8% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 2.7% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (59%)
Current 1,443Won52-week high 1,83852-week low 863
1-month return4.0Point
1m +3.37% (slight rise)
Volume trend6.0Point
Volume surge
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral정기주주총회결과2026-03-31
- Neutral[첨부정정]의결권대리행사권유참고서류2026-03-30
- Neutral감사보고서제출2026-03-23
- Neutral사업보고서 (2025.12)2026-03-23